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INTRODUCTION 
 Hypertension and tachycardia have been reported since 1950 during 
intubation in a light plane of anesthesia. Increase in blood pressure and heart 
rate occurs most commonly from reflex sympathetic discharge in response to 
laryngo tracheal stimulation, which in turn causes increased plasma 
norepinephrine concentration. These changes may be fatal in patients with 
ischeamic heart disease and hypertension. 
 Tachycardia, hypertension and dysrythymias all occur during 
laryngoscopy and intubations. The consequent rise in rate/pressure product may 
result in a myocardial oxygen demand which exceeds the oxygen supply 
resulting in myocardial ischeamia. This response is sympathetically mediated 
and can be attenuated by calcium channel blocking drugs. Studies have 
documented myocardial ischeamic changes due to reflex sympatho adrenal 
response immediately following laryngoscopy and intubation with a mean 
increase in systemic pressure of 40mmHg even in normotensive patients. 
 An increase in heart rate is more likely to produce signs of myocardial 
ischeamia than hypertension on the ECG. Indeed, in anaesthetized patient, the 
incidence of myocardial ischeamia on the ECG sharply increases in patients 
who experience a heart rate greater than 110bpm (ischeamic threshold). A 
frequent recommendation is to maintain heart rate and blood pressure within 
20% of normal awake value for that patient. 
 Many attempts have been made to attenuate the pressor response to 
laryngoscopy and intubation. 
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For eg. 
• deep plane of anesthesia 
• topical anesthesia 
• use of ganglionic blockers 
• use of intravenous local anaesthetics 
• Sodium nitroprusside infusion 
• Magnesium sulphate 
• Fentanyl 
• Use of beta-blockers 
• Calcium channel blockers. 
It has been clearly proven by various studies that sympathetic 
overactivity occurs during laryngoscopy and the importance of suppressing the 
sympathetic overactivity is well emphasized. The various methods of 
suppressing the stress response are listed above, and of these, IV Diltiazem 
appears to be superior to IV Lignocaine. The use of IV diltiazem in suppressing 
the stress response is compared with IV lignocaine in E.N.T surgical patients, 
who underwent FESS, Mastoidectomy etc. 
Lignocaine is the drug that is commonly used in our hospital for 
controlling intubation response. Diltiazem, a calcium channel blocker has been 
found in various studies to attenuate intubation response, hence we made a 
study by comparing Diltiazem and Lignocaine for obtunding intubation 
response, in the Department of Anaesthesiology at Govt. General Hospital, 
Chennai-600 003. 
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AIM OF STUDY 
 To compare the efficacy of IV lignocaine and IV Diltiazem in 
attenuating the cardiovascular stress response during laryngoscopy and 
intubation in E.N.T Surgeries. 
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ANATOMY - NERVE SUPPLY OF LARYNX 
 Nerve supply of larynx is from Superior laryngeal nerve and Recurrent 
laryngeal nerve, which are branches of vagus nerve. 
 Superior laryngeal nerve arises from the middle of the inferior ganglion 
of the vagus, runs downwards and forwards on the superior constrictor muscle 
deep to internal carotid artery and reaches the middle constrictor muscle where 
it divides into external laryngeal nerve and internal laryngeal nerve. External 
laryngeal nerve is thin, accompanies superior thyroid artery, pierces deep 
constrictor and ends by supplying the cricothyroid muscle. 
 Right recurrent laryngeal nerve arises from vagus in front of right 
subclavian artery, winds backwards below the artery to reach the tracheo-
oesophageal groove. It is related to the inferior thyroid artery in its upper part. 
The nerve then passes deep to lower border of inferior constrictor muscle, and 
enters the larynx behind the cricothyroid joint. It supplies all the intrinsic 
muscles of the larynx except the crico thyroid and carries sensory fibres to the 
larynx below the level of vocal cord. 
 The left recurrent laryngeal nerve arises from the vagus in the thorax. It 
curves around the aortic arch and soon gains entry into the tracheo-oesophageal 
groove. Thereafter its course is similar to that of the right recurrent laryngeal 
nerve. 
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PHYSIOLOGY -REFLEX CIRCULATORY RESPONSE TO  
LARYNGOSCOPY AND INTUBATION 
 Hypertension and tachycardia frequently accompany laryngoscopy and 
endotracheal intubation. These circulatory changes are transient and of little 
significance in patients with normal heart. Hypertension and tachycardia 
following laryngoscopy and intubation is due to increase in plasma 
catecholamine concentration, which is more pronounced in ischeamic heart 
disease patients leading to deleterious effect. These reflex circulatory changes 
occur due to stimulation of sympatho adrenal response to noxious stimuli. 
Cardiac arrhythmias occur in 5% to 15% of patients during endotracheal 
intubation under light plane of anaesthesia. Sudden death, presumably from 
ventricular fibrillation, has also been reported to result reflexly from intubation. 
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METHODS TO ATTENUATE CIRCULATORY 
RESPONSE TO LARYNGOSCOPY AND INTUBATION 
 Hypertension and tachycardia have been reported since 1950 during 
intubation in a light plane of anaesthesia. Increase in blood pressure and heart 
rate occurs most commonly from reflex sympathetic discharge in response to 
laryngotracheal stimulation which in turn leads to increased plasma 
norepinephrine concentration, which may be fatal in patients with heart disease 
and hypertension. 
 Many attempts have been made to attenuate the pressor response. 
They are : 
• Deepening the plane of anaesthesia with volatile inhalation agent 
• Topical anaesthesia with xylocaine spray 
• Use of ganglionic blockers 
• Use of beta blockers  
• Sodium nitroprusside infusion 
• Nitroglycerine infusion 
• Calcium channel blockers - Diltiazem 
• Magnesium sulphate 
• Opioids like fentanyl 
• Anti-hypertensive like phentolamine 
• use of IV lignocaine 
• Alpha-agonist like Clonidine. 
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Sodium nitroprusside and nitroglycerine are effective but requires 
continuous intra arterial blood pressure monitoring. 
Calcium channel blockers are effective because myocardial depression 
produced by it is minimised by reduction in afterload, so that cardiac output 
remains unchanged. 
Magnesium sulphate can also be used to control the hypertensive 
response by reducing the plasma norepinephrine concentration. 
Addition of a potent analgesic such as fentanly also attenuates the 
intubation response. 
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PHARMACOLOGY CALCIUM CHANNEL BLOCKERS 
 Calcium channel blockers are a diverse group of structurally unrelated 
compounds that selectively interfere with inward calcium ion movement across 
myocardial and vascular smooth muscle cells (Durand, et al., 1991, Kaplan, 
1989) Calcium ions play a key role in the electrical excitation of cardiac cells 
and vascular smooth muscle cells. 
CLASSIFICATION 
 Commercially available calcium channel blockers are classified on the 
basis of chemical structure as 
a. Phenyl alkylamines 
b. 1,4 dihydropyridines  
c. Benzothiazepines 
These drugs block calcium entry into cardiac and vascular smooth 
muscle cells at the alpha, sub unit, 1,4 dihydropyrimidines are selective for the 
arteriolar beds where as the phenyl alkalamines and benzothiazipines are 
selective for the atrioventricular node. 
MECHANISM OF ACTION 
 Voltage gated calcium ion channels are present in the cell membranes of 
skeletal muscle, vascular smooth muscle, cardiac muscle, mesentric muscle, 
glandular cells and neurons. Of the two types T and L of voltage gated 
channels present in the cardiovascular system, the L-type is the main channels 
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for slow and sustained calcium ions entry into vascular smooth muscle cells. 
Even though the T-type channels are also present on vascular smooth muscle 
cell membranes, insignificant amounts of calcium ions enter cells through 
them, and they are not influenced significantly by calcium channel blockers. 
 The L-type channel has five  sub units alpha, alpha 2, beta, gamma and 
delta. The alpha, sub unit forms the central part of the channel and provides the 
main pathway for calcium ions entry into cells. 
 Direct activation of the vascular smooth muscle cell voltage-gated 
channels by nervous stimuli initiates an action potential, calcium ion influx, 
and myofilament contraction. This process is known as excitation contraction 
coupling. The intracellular calcium  combines with calmodulin, the calcium 
binding protein, to form the calcium - calmodulin complex. This complex 
activates myosin and causes the formation of cross bridges with actin. These 
cross bridges begin the process of muscular contraction. 
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PHARMACOLOGY OF  DILTIAZEM 
 
 
 
 
 
 
 
Chemical 
 A benzothiazipine, a calcium channel blocker 
Main actions 
 It increases myocardial oxygen supply and decreases myocardial oxygen 
demand by coronary artery dilation, possibly aided by direct and indirect 
haemodynamic alterations. 
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Mode of Action 
 Diltiazem acts dose dependent inhibition of the slow inward calcium 
current in normal cardiac tissue. 
Route of Administration / Doses 
 The adult oral dose is 30-120 mg 6-8th hrly. 
Effects 
CVS  : Diltizem is a potent peripheral and coronary arterial vasodilator, 
leading to a decrease in the systemic and pulmonary vascular resistances; the 
cardiac output increases due to a reduction in after load. Little effect on the 
heart rate occurs in man, bradycardia tends to occur with chronic use. A-V 
nodal conduction is decreased by the drug, diltiazem is thus of use in the 
treatment of supra ventricular tachycardia. 
RS : Inhibits bronchoconstriction due to inhaled histamine in man. 
AS : A significant reduction in lower oesophageal pressure is produced 
in patients with achalasia, although no effect is seen in normal patients. 
GU : Renal artery dilation leading to an increased renal plasma flow and 
subsequent diuresis occurs after the administration of diltiazem. Uterine 
activity is decreased invitro. 
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Metabolic 
 Platelet aggregation is decreased by diltiazem invitro, although no 
significant effect on haemostasis can be demonstrated invivo. 
Side effects 
 Occur in 2-10% and include headache, flushing, peripheral oedema and 
bradycardia. 
Kinetics 
 Absorption : 90% of an oral dose is absorbed, the bioavailability by this 
route is 33-40% due to significant first effect. 
Distribution : 78-87% protein bound in the plasma. 
Metabolism : By deacetylation and demethylation in the liver with 
subsequent conjugation to glucuronide and sulphates - the metabolites are 
active. 
Excretion: 1-4% excreted unchanged in the urine. The clearance is 11.5 - 
21.3 ml / Kg/min and the elemination half life is 2-7 hrs. Renal failure has no 
effect. 
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Uses 
 In the treatment of  
1. Stable and variant angina 
2. Hypertension 
3. Supraventricular tachycardia 
4. Raynand's phenomenon 
5. Migraine 
6. Oesophageal disorders 
7. Attenuation of stress response to  intubation 
Presentation 
As 60, 90, 120, 180 mg tablets and Inj 5 ml vial containing 5 mg/ml. 
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PHARMACOLOGY OF LIGNOCAINE 
 
 
 
 
 
 
 
 
 Lignocaine was synthesized in 1943 in Sweedan by Lofgren and was 
introduced into clinical practice in 1948. 
DESCRIPTION 
 Lignocaine hydrochloride is 2-diethylamino-aceto-2'6xylilide 
hydrochloride monohydrate. It appears as a white crystalline powder which is 
odourless. It is very soluble in water, freely soluble in chloroform and in 
ethanol and is practically insoluble in ether. 
 15
 Molecular formula - C14H22 N20 Hcl.H20 
 Molecular weight - 288.8 
 Lignocaine hydrochloride injection is a sterile, isotonic solution 
containing lignocaine hydrochloride B.P., 1% or 2%, and sodium chloride, 
B.P., in water for injection. 
 Lignocaine is a week base with amphiphillic property. A hydrophilic 
amine on one side and a lipophillic aromatic residue on the other side and are 
joined through an amide linkage. 
MECHANISM OF ACTION: 
Local anaesthetics block the nerve conduction by decreasing the entry of 
sodium ions during upstroke of action potential. As the concentration of local 
anaesthetic is increased the rate of rise of action potential and maximum 
depolarization decreases causing slowing of conduction. Finally local 
depolarization fails to reach the threshold potential and condition block ensues. 
The local anesthetics interact with a receptor situated within the voltage 
sensitive sodium channel and raise the threshold of channel opening. 
Sodium channel has an activation gate(A) near its extracellular mouth 
and an inactivation gate(I) at the intracellular mouth. In the resting state, the 
activation gate is closed. Threshold depolarization of the membrane opens the 
activation gate allowing sodium ions to flow in along the concentration 
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gradient. Within a few milliseconds inactivation gate closes and ion flow 
ceases. 
The local anaesthetic recepter is located within the channel in its 
intracellular half. Local anaesthetic traverses the membrane in its lipophillic 
form (B+), reionises in the axoplasm and approaches  the LA receptor through 
the intracellular mouth of the channel. It is the cationic form of local 
anaesthetic (BH+), which primarily binds to the LA receptor. The receptor has 
higher affinity or is more accessible to local anaesthetic in the activated state 
compared to the resting state. Binding of LA to its receptor stabilizes the 
channel in the inactive state and thus reduces the probability of channel 
opening. 
Action of receptors within the sodium channel accounts for 90% of 
nerve blocking effect. Non-specific membrane expansion accounts for the 
remaining 10% of the action and is analogous to the electrical stabilization 
produced by a number of non-polar, purely lipid solvable substances such as 
barbiturates, general anaesthetics and benzocaine. 
PHARMACOLOGICAL ACTION: 
1. LOCAL - Minimal local irritant action and blocks sensory nerve 
endings, nerve trunks, neuro-muscular junction, ganglionic 
receptors. 
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2. REGIONAL - Autonomic fibers are generally more susceptible 
than somatic fibers. Among the somatic afferents, the order of 
blockade is pain temperature touch deep pressure. 
 3. SYSTEMIC - Effect is mainly on CVS or CNS. 
 CVS : In cardiac tissue, a therapeutic serum concentration (1.5 to 
6. micrograms / ml) of lignocaine will produce the following effects: 
• depression of slow spontaneous depolarization (phase 4), that is the 
automaticity of isolated, non-polarised purkinjee fibres, while having 
little effect on conduction velocity, membrane responsiveness or 
cardiac output. Automaticity induced by stretch, hypoxia or 
catecholamines can also be suppressed by lignocaine. 
• Shortening of action potential period and effective refractory period 
of purkinjee and ventricular cells. 
 Thus it has a stabilizing effect on cell membrane of cardiac tissue. It also 
stabilizes aberrant conduction. 
 CNS : Low plasma concentration of LA are likely to produce 
numbness of tongue and circumoral tisses. As plasma concentration increases it 
crosses blood-brain-barrier and produces restlessness, vertigo, tinitus and 
difficulty in focusing. Then slurred speech and skeletal muscle twitching occur. 
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Lignocaine causes drowsiness before seizures. Seizures are classically followed 
by CNS depression, which may be accompanied by hypotension and apnoea. 
PHARMACOKINETICS 
 Following IV injection, the blood level of lignocaine declines with a 
half-life of 7 to 10 mins., within the first hour due to rapid distribution into 
various tissues including the heart. After this initial phase, the half-life is 90 to 
120 mins (metabolism and excretion). Absorption is slow in regional 
anaesthesia. 
METABOLISM AND EXCRETION 
 The principle metabolic pathway of lignocaine is oxidative dealkylation 
in the liver to monoethylgycinexylidine following by hydrolysis of this 
metabolite to xylidine. Monoethylglycine xylidine has approximately 80% of 
the activity of lignocaine for protecting against cardiac dysrhythmias. This 
metabolite has a prolonged elimination half time. Xylidine has approximately 
10% of the activity of lignocaine. Hepatic disease or decrease in hepaticflow, 
which may occur during general anaesthesia, decreases the rate of metabolism 
of lignocaine. Excretion is through the kidneys. Approximately 90% of the 
dose is excreted as metabolites and less than 10% is excreted unchanged in the 
urine. 
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DOSAGE 
 For cardiac arrythmias, therapeutic serum concentration of lignocaine is 
5 to 20 micromol/L or 1.5 to 6.0 micrograms/ ml. 
 A single intravenous dose of 1mg/kg should be given over 1 to 2 mins, 
to obtain therapeutic blood levels rapidly. The initial effect will occur in 2 to 4 
mins, and may last as long as 20 mins. This should be followed within 10 mins, 
by a continuos infusion at the rate of 2 to 4 mgs/min. The initial dose may be 
repeated by two more injections at 15 to 20 min intervals to maintain 
therapeutic blood levels but no more than 300mg of lignocaine should be 
administered within a 1 hr period. Since it has a very narrow therapeutic 
window, infusion should promptly stopped when there is an undue 
prolongation of PR interval or QRS complex. 
 To attenuate the cardiovascular stress response to intubation, lignocaine 
1.5mg/kg IV 3 min prior to laryngoscope should be given. 
ADVERSE EFFECTS /TOXCICITY: 
• Due to high plasma levels as a result of excessive dosage, rapid 
absorption, delayed elimination or inadvertent IM injection during local 
anaesthetic use. 
• CNS: Lightheadedness, disorientation, confusion, psychois, 
nervousness, agitation, drowsiness, euphoria, tinnitus, blurred vision, 
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slurred speech, numbness, twitcfhing, tremors, convulsions, 
unconsiousness, seizures, coma, respiratory depression and arrest. 
• CVS: Hypotension, CVS collapse, arrahythmias, heart block and 
bradycardia which may lead to cardiac arrest. Meth-hemoglobineamia 
may occur following IV administration. 
• HYPERSENSITIVITY: Rare with lignocaine. 
• NEUROLOGICAL SYSTEM : Persistent anaestheisa, paresthesia, 
weakness, paraplegia of lower extremeities and loss of sphincter control 
may occur. 
PRECAUTIONS 
 The safety and effectiveness of lignocaine depends upon proper dosage, 
correct technique, adequate precautions and readiness for emergencies. 
1. Lignocaine should be given cautiously in patients with severe 
bradycardia, cardiac conduction disturbances, severe digitalis 
intoxication, severe shock and hypovolemia. 
2. Serum Potassium level should be normalized prior to administration of 
lignocaine as anti-arryhthmic drugs may be ineffective in hypokaelemic 
patients. 
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DRUG INTERACTIONS 
 Propanolol and metaprolol reduce the metabolism of intravenously 
administered lignocaine. It is possible that this effect will be repeated with 
other beta - adrenergic blockers. 
1. Phenytoin, phenobarbitone, primidone and carbamazapine appears to 
enhance the metabolism of lignocaine, possible due to an induction of 
microsomal enzyme. 
2. Lignocaine prolongs the duration of suxamethonium. 
INDICATIONS 
 1. Local anaesthesia, nerve blocks and regional analgesia. 
 2. Anti-arrhythmic agent. 
 3. To obtund intubation response 
 4. Brain Protection. 
 5. Myocardial infarction. 
6. To relieve arterial spasm following accidental intra-arterial 
injection of Thiopentone. 
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RIED & BRACE (1940) postulated that reflex circulatory 
responses to laryngeal instrumentation were mediated through the vagus 
nerve and they named it as "Vaso Vagal Reflex". 
KING et al (1951) used deep ether anaesthesia to abolish the 
reflex circulatory response to tracheal intubation. 
WYCOFF C.C. (1960) in his study stated that topical anaesthesia 
of the pharynx along with superior laryngeal nerve blocks, reduced the 
increase in mean arterial pressure after intubation. 
STEINHANS GASKIN (1963) found that intravenous lignocaine 
suppressed the cough reflex. It is very easy to predict that if the cough is 
suppressed, the rise in blood pressure and pulse rate and intra cranial  
pressure noticed on laryngeal instrumentation would be blunted by this 
technique. 
FORBES and DALLY (1970) observed that laryngoscopy and 
endo-tracheal intubation is immediately associated with an average 
increase in mean arteral pressure of 25mm Hg in all 22 normotensive 
patients. These responses were interpreted as due to reflex sympathetic 
adrenal stimulation.  
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MASSON AND ECKANKOFF (1971) proved that the 
hypertensive response in patients can be significantly decreased by 
simple lignocaine spray. 
PRY ROBERT et al (1971) found that the increase in heart rate 
and blood pressure are much more exaggerated in hypertensive patients. 
DENLINGEAR J.K. and ELLISON N.E. (1974) have used 
intratracheal lignocaine spray which causes a 50% reduction in the 
hypertensive response. 
VICTORIA FARIA BALNC and NORMAND A.G. (1974) in 
their article of "complications of tracheal Intubation" have classified the 
neurogenic or reflexly mediated complication into three different 
categories. 
i. Laryngo Vagal Reflexes - Which give rise to spasm of the 
glottis, bronchospasm, apnoea, bradycardia, cardiac 
dysrrhythmias and arterial hypotension. The mere presence of the 
tracheal tube seem to be the most common cause of 
bronchospasm in anesthetised asthmatic patients. 
ii. Laryngo Sympathetic Reflexes - Which include tachycardia, 
tachyarrhythmias, acute arterial hypertension as frequent 
complication. The hypertensive hyperdynamic state during 
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laryngoscopy may be related in some cases to  an increased nor-
adrenaline fraction of the total catecholamines. 
iii. Laryngo Spinal Reflexes - Which include coughing, vomiting 
and bucking. 
RICHARD McCAMMAN (1981) studies the effects of propranolol and 
they significantly proved that better protection was given by the administration 
of topical lignocaine or intravenous lignocaine in patients who were on chronic 
propranolol therapy. 
DONAL E. MARTIN (1982) have also proved the efficacy of a low 
dose fentanyl along with an induction dose of thiopentone, but in these series, it 
was also found that the incidence and occurrence of tachycardia was not 
prevented. 
TAM.S. et at (1985) found attenuation of circulatory responses to 
laryngoscopy and endotracheal intubation using intravenous lignocaine; a 
determination of the optimal time as 3 minutes before intubation. 
DONAL R MILLER and RAYMOND J. MARTINEAN (1989) used 
bolus dose of esmolol for treating hypertension, tachycardia and myocardial 
ischaemia intra operatively. 
T. NISHINO, K. HIRAGA and K. SUGIMORI in (1990) proved that 
intravenous lignocaine had a dose dependent effect on the expiration  reflex, 
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cough reflex in patients anaesthetized with enflurane,  and that 1.5mg/kg of 
lignocaine intravenous can suppress the cough reflex and other related reflexes 
during intubation, extubation, bronchoscopy and laryngoscopy when duration 
of these procedures is relatively brief. 
C.D. MILLER and S.J. WARREN (1990) observed that intravenous 
lignocaine given within three minutes had no significant effect on 
cardiovascular effects of laryngoscopy and Intubation. 
STEVEN M. HELFMAN, MARTIN I GOLD, EVERTARD, A DE 
LESSER and CLAIRE A. HERRINGTON (1991) observed that esmolol 
provides consistent and reliable protection from increase in both heart rate and 
systolic blood pressure during and after intubation where as lignocaine and 
fentanyl failed to protect against increase in heart rate but did not provide 
protection against increase in systolic blood pressure equivalent to that 
provided by esmolol. 
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MATERIALS AND METHODS 
 A prospective study comparing Diltiazem and Lignocaine in attenuating 
the haemodynamic response to laryngoscopy and intubation in E.N.T. patients 
comprised of 40 patients aged between 20 to 50 years. Both male and female 
patients who were scheduled for E.N.T. procedures like FESS, mastoidectomy, 
myringoplasty, Stepedectomy etc. requiring endotracheal intubation were 
chosen for the study. All patients belonged to ASA I physical status. Patients 
with cardio-respiratory problems and patients suspected to have a difficult 
intubation were excluded from the study. All the patients were informed of the 
study and their consent was obtained. The surgeon was also informed of the 
study. 
 Patients were assessed by a detailed examination, including, X-ray 
chest, ECG and routine laboratory tests. In this study, patients were randomly 
assinged into 2 groups. 
 Group `A' - 20 patients received Diltiazem by intravenous bolus 
administration in a dose of 0.2 mg/Kg body weight, 1 min prior to intubation. 
Group `B' - 20 patients received Lignocaine by intravenous 
administration in a dose of 1.5 mg/kg body weight, 3 mins prior to intubation. 
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ANAESTHESIA PROTOCOL 
 Preoprative visit was done to allay anxiety, and a good rapport was 
established with the patient. 
PREMEDICATION 
 All patients were given inj. Glycopyrrolate 5 micrograms/kg body 
weight and inj. Pentazocine 0.6 mg/kg body weight intramuscularly 45 mins 
before surgery. Pre-operative heart rate and blood pressure were recorded. 
INDUCTION AND INTUBATION 
 Pre-oxygenation was done for 3 mins. Baseline heart rate, blood 
pressure and ECG were recorded. Then the patient was induced with inj. 
Thiopentone 5 mg/kg body weight followed by inj. vecuronium 0.1 mg/kg 
body weight. Intubation was done 4 Min. after induction Intubation was done 1 
min after test drug diltiazem and 3 mins after the test drug Lignocaine with the 
appropriate size cuffed endo-tracheal tube. 
MAINTENANCE 
 Anaesthesia was maintained with Nitrous oxide and Oxygen. No 
surgical stimulation was permitted for 5 mins after intubation. 
MONITORING 
 Monitoring devices - NIBP, ECG, Pulse-oximeter were connected to the 
patient. Blood pressue was recorded every minute upto 5 mins. 
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PROFORMA 
 
COMPARISON OF DILTIAZEM AND LIGNOCAINE FOR 
ATTENUATING INTUBATION RESPONSE 
 
 
Name :    Age :  Sex :  Wt : 
 
IP No :    ASA Physical Status : 
 
Diagnosis :    Procedure : 
 
Pre medication : Glycopyrrolate 0.2 mg IM 
   Pentazocine 0.6 mg/kg body wt. 
 
Induction :  Thiopentone sodium 5 mg/kg body wt. 
 
Intubation :  vecuronium 0.1 mg/kg body wt. 
 
Trial drug :  Group A - diltiazem 0.2 mg/kg body wt. 1 min prior to 
   intubation 
 
   Group B - Lignocaine 1.5 mg/kg body wt 3 min prior to 
   intubation. 
 
Intubation was done 4 minutes after induction. 
 
Time Pre induction 
1 min 
after 
Trial 
Drug 
Intubation 1 min
2 
min 
3 
min 
4 
min 
5 
min
HR         
Systolic 
BP 
        
Diastolic 
BP 
        
MAP         
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OBSERVATION AND RESULTS 
 40 patients under this study were categorised into two groups. They 
comprised both sexes in the age group of 20 to 50 years. The age and sex 
distribution was equal in all the two groups. 
The groups are : 
1. Diltiazem (Group- A) : Consisting of 20 patients who received 
inj. Diltiazem 0.2 mg/kg body weight, bolus 1 min. prior to 
laryngoscopy. 
2. Lignocaine (Group `B') consisting of 20 patients who received 
Inj. Lignocaine 1.5 mg/kg body weight, 3 mins prior to 
Laryngoscopy. 
Heart rate and Blood pressure were recorded before induction, 1 min 
after test drug, at the time of intubation and every 1 min for 5 mins. 
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Table 1  
PATIENTS CHARACTERISTICS 
 Group A (Diltiazem) Group B (lignocaine) 
Patients (n) 20 20 
Age (yr) 31 +/- 7.244  
(mean +/- SD) 
30.5 +/- 8.007 
(mean +/- SD) 
Sex (M/F) 11/9 10/10 
Weight (Kg) 55.7 +/- 5.63 
(mean +/- SD) 
52.6 +/- 6.866 
(mean +/- SD) 
 
P value for age = 0.79 
P value for body weight = 0.06 
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Table 2 
 
HEART RATE 
 
 Group N Mean SD 
Students t-test 
and Mean 
difference 
with 95% CI 
Statistical 
Significance 
Pre induction 
  
Diltiazem 20 83.25 7.412
t=0.93  p=0.36 NS 
Lignocaine 20 80.65 10.111
One min after 
drug 
Diltiazem 20 100.40 6.541
t=1.65  p=0.11 NS 
Lignocaine 20 96.40 8.647
Intubation 
  
Diltiazem 20 106.25 6.455 t=1.99  p=0.05 
5.6(1-11) 
S 
Lignocaine 20 111.85 10.888
One minute 
  
Diltiazem 20 105.05 7.543 t=2.74  p=0.01 
8(2-14) 
S 
Lignocaine 20 113.05 10.674
Two minutes 
  
Diltiazem 20 102.40 7.816 t=2.53  p=0.02 
7.8(2-14) 
S 
Lignocaine 20 110.15 11.207
Three minutes 
  
Diltiazem 20 98.40 7.923 t=3.89 
p=0.001 
11.7(6-18) 
S Lignocaine 20 110.05 10.787
Four minutes 
  
Diltiazem 20 97.85 7.286 t=3.4  p=0.002 
10(4-16) 
S 
Lignocaine 20 107.85 10.946
Five minutes 
  
Diltiazem 20 95.15 5.613 t=3.60 
p=0.001 
10.5(5-17) 
S Lignocaine 20 105.65 11.775
 
C.I. = Confidence Interval 
p value < 0.05 is significant 
 
 The data were analysed using Analysis of variance and results were 
considered statistically significant if is p value is < 0.05 
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Table 3 
BLOOD PRESSURE (mm of Hg) 
 
 Group N Mean SD 
students t- test 
and Mean difference with 
95% CI 
Statistical 
Significance 
Pre induction 
_sbp 
Diltiazem 20 119.90 9.486
t=0.48  p=0.64 NS 
Lignocaine 20 118.50 9.168
Pre induction 
_dbp 
Diltiazem 20 79.05 7.584
t=0.67  p=0.51 NS 
Lignocaine 20 80.50 6.022
one min drug 
sbp 
Diltiazem 20 106.70 11.361 t=3.36  p=0.002 
10.9(4-17) 
S 
Lignocaine 20 117.60 9.058
one min drug 
_dbp 
Diltiazem 20 69.55 9.451 t=4.03  p=0.001 
9.8(5-15) 
S 
Lignocaine 20 79.30 5.292
intubation_sbp 
  
Diltiazem 20 121.00 10.657 t=4.03  p=0.001 
22.9(17-29) 
S 
Lignocaine 20 143.85 8.437
intubation_dbp 
  
Diltiazem 20 80.05 8.217 t=7.52  p=0.001 
14.9(11-19) 
S 
Lignocaine 20 94.90 4.962
one min_sbp 
  
Diltiazem 20 132.00 11.300 t=6.92  p=0.001 
11.5(5-18) 
S 
Lignocaine 20 143.50 8.859
one min_dbp 
  
Diltiazem 20 88.40 8.042 t=3.58  p=0.001 
6.8(3-11) 
S 
Lignocaine 20 95.20 4.927
two min_sbp 
  
Diltiazem 20 130.20 9.390 t=3.22  p=0.003 
12.3(7-18) 
S 
Lignocaine 20 142.45 8.049
two min_dbp 
  
Diltiazem 20 87.95 6.770 t=4.43  p=0.001 
5.1(2-8) 
S 
Lignocaine 20 93.05 4.662
three min_sbp 
  
Diltiazem 20 127.75 8.735 t=2.78  p=0.009 
11.5(6-17) 
S 
Lignocaine 20 139.25 8.908
three min_dbp 
  
Diltiazem 20 85.85 7.058 t=4.12  p=0.001 
5.7(2-10) 
S 
Lignocaine 20 91.55 5.083
four min_sbp 
  
Diltiazem 20 125.50 10.195 t=2.93  p=0.006 
9.5(4-15) 
S 
Lignocaine 20 135.00 6.875
four min_dbp 
  
Diltiazem 20 84.35 6.831 t=3.46  p=0.001 
5.9(2-9) 
S 
Lignocaine 20 90.20 3.651
five min_sbp 
  
Diltiazem 20 121.70 8.749 t=4.59  p=0.001 
11.6(7-18) 
S 
Lignocaine 20 133.30 7.168
five min_dbp 
  
Diltiazem 20 80.90 5.830 t=4.51  p=0.001 
7.3(4-11) 
S 
Lignocaine 20 88.20 4.287
 
sbp : Systolic blood pressure 
dbp : diastolic blood pressure 
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Graph II 
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Graph III 
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Table 4 
PRE INDUCTION - MEAN HEART RATE 
 
Group N Mean SD Students t_test and Mean difference with 95% CI 
Diltiazem 'A' 20 83.25 7.412 t = 0.93 
P = 0.36 Lignocaine 'B' 20 80.65 10.111 
 
By student t-test and mean difference with 95% confidence Interval 
Heart rate : No significant difference. 
 
Table 5 
1 MIN AFTER TEST DRUG - MEAN HEART RATE 
Group N Mean SD Students t_test and Mean difference with 95% CI 
Diltiazem 'A' 20 100.40 6.541 t = 1.65 
P = 0.11 Lignocaine 'B' 20 96.40 8.647 
 
Heart rate not significant 
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Table 6 
INTUBATION - MEAN HEART RATE 
 
Group N Mean SD Students t_test and Mean difference with 95% CI 
Diltiazem 'A' 20 106.25 6.455 t = 1.99 
P = 0.05  
5.6 (1-11) 
Lignocaine 'B' 20 111.85 10.888 
 
 
If P value is < 0.05 significant 
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Table 7 
HEART RATE - 1-5 MINS AFTER INTUBATION 
 
Group N Mean SD Students t_test and Mean difference with 95% CI 
1 
min 
Diltiazem 'A' 20 105.05 7.543 t = 2.74, p = 0.01  
8 (2 - 14) 
Lignocaine 'B' 20 113.05 10.674 
2 
mins 
Diltiazem 'A' 20 102.40 7.816 t = 2.53,  p = 0.02 
7.8 (2-14) 
Lignocaine 'B' 20 110.15 11.207 
3 
mins 
Diltiazem 'A' 20 98.40 7.923 t = 3.89  p = 0.001 
11.7 (6 - 18) 
Lignocaine 'B' 20 110.05 10.787 
4 
mins 
Diltiazem 'A' 20 97.85 7.286 t = 3.4, p = 0.002 
10 (4 - 16) 
Lignocaine 'B' 20 107.85 10.946 
5 
mins 
Diltiazem 'A' 20 95.15 5.613 t = 3.60 p = 0.001 
10.5 (5-17) 
Lignocaine 'B' 20 105.65 1.775 
 
P value < 0.05 is significant 
In 1- 5 mts after intubation there is a significant difference variation is 2-18 
bpm. 
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Table 8 
MEAN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE  
 
AT PRE INDUCTION 
 
 
 
Group N Mean SD 
Students t_test and 
Mean difference 
with 95% CI 
SBP Diltiazem 'A' 20 119.90 9.486 t = 0.48 
P = 0.64 Lignocaine 'B' 20 118.50 9.168 
DBP Diltiazem 'A' 20 79.05 7.584 t = 0.67 
p = 0.51 Lignocaine 'B' 20 80.50 6.022 
 
Not significant 
 
Table 9 
MEAN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE 1 MIN, 
AFTER TEST DRUG 
 
Group N Mean SD 
Students t_test and 
Mean difference 
with 95% CI 
SBP Diltiazem 'A' 20 106.70 11.361 t = 3.36   P = 0.002 
10.9 (4 - 17) Lignocaine 'B' 20 117.60 9.058 
DBP Diltiazem 'A' 20 69.55 9.451 t = 4.03   p 0.01 
9.8 (5 - 15) Lignocaine 'B' 20 79.30 5.292 
 
P value is < 0.05. This is signifant, 
 Systolic BP diference is 4 - 17 mm of Hg 
 Diastolic BP difference is 5 - 15 mm of Hg 
This difference is significant. 
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Table 10 
 
MEAN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE  
AT INTUBATION 
 
 
Group N Mean SD 
Students t_test and 
Mean difference 
with 95% CI 
SBP Diltiazem 'A' 20 121.00 16.657 t = 4.03  p = 0.001 
22.9 (17-29) Lignocaine 'B' 20 143.85 8.437 
DBP Diltiazem 'A' 20 80.05 8.217 t = 7.52  p = 0.001 
14.9 (11-19) Lignocaine 'B' 20 94.90 4.968 
 
Mean systolic Blood Pressure varies between 17-29 mm of Hg 
Mean Diastolic Blood Pressure varies between 1-19 mm of Hg  
Both values are significant. 
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Table 11 
MEAN SYSTOLIC AND DIASTOLIC BLOOD PRESSURE 1-5 MINS. 
AFTER INTUBATION 
Group N Mean SD 
Students t_test and 
Mean difference 
with 95% CI 
1 min SBP Diltiazem 'A' 20 132.00 11.300 t = 6.92  p = 0.001 
11.5 (5 - 18) Lignocaine 'B' 20 143.50 8.859 
DBP Diltiazem 'A' 20 88.40 8.042 t = 3.58  p = 0.001 
6.8 (3 - 11) Lignocaine 'B' 20 95.20 4.927 
2 mins SBP Diltiazem 'A' 20 130.20 9.390 t = 3.22  p = 0.003 
12.3 (7 - 18) Lignocaine 'B' 20 142.45 8.049 
DBP Diltiazem 'A' 20 87.95 6.770 t = 4.43  p = 0.001 
5.1 (2-8) Lignocaine 'B' 20 93.05 4.662 
3 mins SBP Diltiazem 'A' 20 127.75 8.735 t = 2.78  p = 0.009 
11.5  (6-17) Lignocaine 'B' 20 139.25 8.908 
DBP Diltiazem 'A' 20 85.85 7.058 t = 4.12  p = 0.001 
5.7 (2 - 10) Lignocaine 'B' 20 91.55 5.083 
4 mins SBP Diltiazem 'A' 20 125.50 10.195 t = 2.93   p = 0.006
9.5 (4 - 15) Lignocaine 'B' 20 135.00 6.875 
DBP Diltiazem 'A' 20 84.35 6.831 t = 3.46  p = 0.001 
5.9 (2 - 9) Lignocaine 'B' 20 90.20 3.651 
5 mins SBP Diltiazem 'A' 20 121.70 8.749 t = 4.59  p = 0.001 
11.6 (7 - 18) Lignocaine 'B' 20 133.30 7.168 
DBP Diltiazem 'A' 20 80.90 5.830 t = 4.51  p = 0.001 
7.3 (4 - 11) Lignocaine 'B' 20 88.20 4.287 
 
In 1 to 5 mts after intubation there is significant difference in systolic and 
Diastolic blood pressure 
Syst. BP varies between 4 - 18 mm of Hg 
Diastolic BP varies between 2 - 11 mm of Hg. 
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 Increase in Heart rate following intubation upto 5 mts is less with 
diltiazem group when compared to Lignocaine group and the difference is 
statistically  significant. There was a slight increase in heart rate immediately 
following the administration of diltiazem however this is not statistically 
significant (Table 2) The results were plotted in a graph (Graph - I) 
 The rise in both systolic and diastolic blood pressure following 
intubation is less with diltiazem group when compared to lignocaine group. 
The result is statistically significant (P < 0.05) blood pressure were measured 
upto 5 mts after intubation (Table 3) There was a slight transient fall in the BP 
immediately after administrate of diltiazem which is not statistically significant 
(> 0.05). The results were plotted in a graph which confirm the statistics 
(Graph II & III). 
• The demographic profile is similar in both the groups. (Table 1) 
• There was no statistically significant difference in pre induction heart 
rate between the two groups. (p value 0.36). 
• From the time of laryngoscopy and intubation upto five minutes 
following intubation there is a statistically significant difference in the 
heart rate between the two groups. (p values at laryngoscopy, 1,2,3,4 &  
5 mins following intubation are 0.01, 0.02, 0.001, 0.002 & 0.001 
respectively. And from the graph it is evident that heart rate following 
intubation was lesser in diltiazem group than lignocaine group. 
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• There is a statistically insignificant difference in the systolic & diastolic, 
at the time of pre induction, and at the time of test drug delivery. 
• From the graph it is evident that there is a statistically significant drop in 
the mean systolic pressure and diastolic pressure in the diltiazem group 
with respect to lignocaine group. 
• There is a statistically significant difference in the mean systolic and 
diastolic pressure between the 2 groups from the time of laryngoscopy 
till 5 min following intubation. It is evident from the graph that they are 
lesser in diltiazem group than lignocaine group. 
This shows Diltiazem is better than the Lignocaine in attenuating stress 
response to laryngoscopy and intubation.  
 47
DISCUSSION 
 Hypertension and tachycardia usually accompany laryngoscopy and 
intubation.[1] This response is undersirable, especially in patients with 
cardiovascular and intracranial disease. Increase in heart rate and blood 
pressure occurs most commonly from reflex sympathetic discharge in response 
to laryngotracheal stimulation, which in turn leads to increased norepinephrine 
levels [4]. 
 Many attempts have been made to attenuate the pressor response by 
many persons with varying success rate. 
 KING et al (1951), [13] used ether to attenuate the pressor response 
while Wycoff [28] et al (1960) [6], and J.KENNETH (1974) tried a 
combination of topical anaesthesia of larynx together with Superior laryngeal 
nerve block to attenuate the stress response to intubation. 
 STEINHAN AND GASKIN (1963) [22] used IV Lignocaine, JAMES et 
al (1981) used Lignocaine intratracheal spray, MASSON & ECKANKOFF 
(1971) and DENLINGER J.K. AND STOELTING (1978) [25] used a 
combination of viscous Lignocaine and topical intratracheal lignocaine. 
 FASSUOULAKI A, KANNIASIS P used intranasal administration of 
Nitro-glycerine to attenuate the pressor response. Anti-hypertensives like 
phentolamine have also been used to attenuate the pressor response by 
DEVAULT M et al. 
 48
 Calcium channel blockers have been used to attenuate the pressor 
response by PURI GD & BATRA YK & NISHI KAWA, T, NAMIKIA. 
 Lignocaine has been found to be ineffective in attenuating the intubation 
response. SING H. VICHITVEJPAISAL et al [22] (1955) showed in their 
study that lignocaine 1.5 mg/kg body weight intravenously was ineffective in 
controlling the heamodynamic response following laryngoscopy and 
intubation. 
 CHAREMMER JORGERREN et al found no beneficial effect when 
Lignocaine 1.5 mg/kg body weight was given 2 mins prior to laryngoscopy. SJ 
WARREN (1990) found that Lignocaine 1.5 mg/kg body weight given more 
than 3 mins before laryngoscopy failed to attenuate the pressor response. 
 Narcotics used to attenuate the intubation response may produce 
respiratory depression whereas inhalational agents may produce cardiovascular 
depression. Use of vasodilators like Sodium nitroprusside may result in reflex 
tachycardia and lability of blood pressure.  
 Calcium channel blockers effectively prevents increase in Heart rate and 
Blood pressure following laryngoscopy by suppressing A-V nodal conduction 
and vasodilatation. 
 In this study the rise in heat rate following intubation is less with 
Diltiazem group than lignocaine group Fujii et al (1995) and Hasegawaj et al 
have observe that diltiazem effectively prevents tachycardia following 
laryngoscopy. 
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 Mikawa K et al (1990) and Fujii Y et al (1998) have found that 
diltiazem attenuates the pressor response following intubation. This concurs 
with our study in which the rise in blood pressure following laryngoscopy is 
less with the diltiazem group than the lignocaine group. 
 No patient in this study developed severe hypotension. The lowest 
systolic and diastolic pressure were recorded 88/56. This concurs with the 
study of K.Mikawa et al (1996). 
 This study shows that Diltiazem is better alternative to lignocaine in 
attenuating the cardiovascular responses to tracheal intubation. This results are 
consistents with the findings of Fujii Y et al (1998). 
 There were no difference between the diltiazem ad lignocaine group in 
the clinical out come (intra-operative and post operative morbidity and 
mortality) possibly because this study was conducted only in ASA I patients, 
without cardiovascular or cerebro vascular diseases. 
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SUMMARY 
 This study was done on patients undergoing E.N.T procedures to 
compare the efficacy of IV Lignocaine and IV Diltiazem for attenuating the 
haemodynamic response to laryngoscopy and intubation. 
 A prospective study was carried out in 40 E.N.T patients in the age 
group 20-50 years requiring endotracheal intubation. The patients were 
randomly assigned into 2 groups. Group I received diltiazem 0.2 mg/kg body 
weight one minute prior to intubation and Group II received lignocaine 1.5 
mg/kg body weight, 3 minutes prior to intubation. 
 The pulse rate systolic and diastolic blood pressure were recorded every 
minute for 5 minutes following laryngoscopy and intubation. 
 The study showed that diltiazem was better than lignocaine in 
attenuating the haemodynamic response to laryngoscopy and intubation in 
E.N.T procedures. The side effects associated with IV diltiazem are negligible 
hence the drug diltiazem is better alternative to lignocaine in attenuating the 
intubation response. 
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CONCLUSION 
From this study it is concluded that diltiazem, given as bolus in a does 
of 0.2 mg/kg body weight 1 minute prior to intubation, is a better alternative to 
lignocaine in attenuating the cardiovasuclar responses to laryngoscopy and 
intubation. 
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PROFORMA 
 
COMPARISON OF DILTIAZEM AND LIGNOCAINE FOR 
ATTENUATING INTUBATION RESPONSE 
 
 
Name :    Age :  Sex :  Wt : 
 
IP No :    ASA Physical Status : 
 
Diagnosis :    Procedure : 
 
Pre medication : Glycopyrrolate 0.2 mg IM 
   Pentazocine 0.6 mg/kg body wt. 
 
Induction :  Thiopentone sodium 5 mg/kg body wt. 
 
Intubation :  vecuronium 0.1 mg/kg body wt. 
 
Trial drug :  Group A - diltiazem 0.2 mg/kg body wt. 1 min prior to 
   intubation 
 
   Group B - Lignocaine 1.5 mg/kg body wt 3 min prior to 
   intubation. 
 
Intubation was done 4 minutes after induction. 
 
Time Pre induction 
1 min 
after 
Trial 
Drug 
Intubation 1 min
2 
min 
3 
min 
4 
min 
5 
min
HR         
Systolic 
BP 
        
Diastolic 
BP 
        
MAP         
 
GROUP  'A'  (DILTIAZEM) BLOOD PRESSURE - SYSTOLIC AND DIASTOLIC (mm of Hg) 
 
S.No. 
Pre induction 1 min after Test drug Intubation 1 min 2 min 3 min 4 min 5 min 
S D S D S D S D S D S D S D S D 
1. 101 67 94 64 104 78 128 84 129 86 118 78 110 74 108 66 
2. 127 86 110 76 122 82 138 92 136 90 130 88 128 86 124 78 
3. 123 73 108 66 118 80 140 88 138 86 130 84 128 82 118 80 
4. 114 71 98 60 110 72 129 84 128 84 126 82 116 80 116 78 
5. 140 88 126 78 134 88 156 100 134 100 130 98 148 99 140 90 
6. 124 82 110 76 122 80 138 94 136 92 134 90 130 88 128 88 
7. 110 72 102 64 108 66 128 88 128 84 126 86 120 84 113 80 
8. 116 80 104 68 114 78 130 90 130 90 128 87 126 88 120 82 
9. 108 66 100 56 110 66 122 83 128 80 128 80 118 78 112 78 
10. 130 90 126 84 130 84 148 100 148 100 140 96 136 90 138 86 
11. 117 83 88 56 118 82 101 67 107 72 106 74 105 74 107 75 
12. 116 74 95 67 141 96 145 97 149 99 150 99 144 99 126 76 
13. 114 82 130 92 128 91 126 90 124 90 123 89 122 88 121 88 
14. 128 83 104 60 130 73 129 72 130 87 122 72 133 77 130 77 
15. 128 90 98 64 116 78 130 90 122 84 129 88 123 81 119 78 
16. 113 75 102 70 140 94 123 87 119 83 119 84 121 85 118 88 
17. 124 81 110 72 120 81 132 90 130 88 128 84 126 82 124 80 
18. 125 80 109 74 119 80 131 90 128 88 128 82 126 80 126 80 
19. 110 70 100 64 108 70 128 88 124 84 126 86 120 84 118 82 
20. 130 88 120 80 128 82 138 94 136 92 134 90 130 88 128 88 
GROUP `B' (LIGNOCAINE) BLOOD PRESSURE - SYSTOLIC AND DIASTOLIC (mm of Hg) 
 
S.No. 
Pre induction 1 min after Test drug Intubation 1 min 2 min 3 min 4 min 5 min 
S D S D S D S D S D S D S D S D 
1. 110 73 106 72 136 90 135 90 133 87 130 84 130 84 128 83 
2. 123 84 128 80 150 93 153 102 150 100 148 98 140 90 140 90 
3. 119 83 116 82 132 97 150 97 148 94 148 86 133 93 130 90 
4. 131 86 123 82 155 102 153 103 150 97 147 93 146 93 144 90 
5. 100 77 102 73 134 92 133 90 130 90 128 87 124 86 122 83 
6. 106 70 113 76 139 89 129 90 137 87 127 85 124 86 122 80 
7. 115 83 110 79 145 105 144 103 144 100 140 96 138 94 136 94 
8. 130 90 130 83 153 96 150 90 149 98 148 96 133 94 132 92 
9. 120 82 118 80 158 97 149 96 148 96 146 92 140 90 144 87 
10. 124 74 124 80 150 96 154 96 150 90 148 87 140 90 133 93 
11. 112 75 108 74 134 88 137 92 135 89 132 86 132 84 130 85 
12. 125 86 130 82 150 91 151 94 150 93 127 96 140 90 140 90 
13. 104 76 110 74 136 87 127 86 127 86 127 85 124 86 122 80 
14. 128 86 124 80 140 98 140 99 138 96 137 95 130 90 128 88 
15. 122 83 120 81 142 96 148 98 146 96 145 95 140 92 138 90 
16. 115 82 110 79 143 100 143 98 143 87 142 96 140 94 136 90 
17. 110 70 106 68 130 88 129 89 128 88 126 86 126 86 125 85 
18. 126 80 126 86 148 98 149 99 148 98 147 98 136 94 138 88 
19. 130 90 130 91 154 98 150 96 149 94 148 96 140 94 140 94 
20. 120 80 118 84 148 97 146 96 146 95 144 94 144 94 138 92 
GROUP 'A' (DILTIAZEM) HEART RATE (BEATS PER MINUTE) 
 
S.No. Pre induction 
1 m after 
Test drug Intubation 1 min 2 min 3 min 4 min 5 min 
1. 82 94 106 114 110 101 106 100 
2. 95 108 117 117 115 109 111 105 
3. 90 98 113 106 104 96 96 94 
4. 84 96 108 104 106 104 102 98 
5. 72 98 102 100 100 98 98 94 
6. 80 100 104 109 98 92 90 92 
7. 80 104 100 98 96 92 90 92 
8. 78 98 106 105 104 105 100 97 
9. 78 96 94 90 86 82 87 84 
10. 90 116 110 108 100 96 94 94 
11. 97 109 118 117 117 110 112 106 
12. 90 98 113 106 104 96 96 94 
13. 80 100 104 104 98 92 90 92 
14. 84 96 108 104 106 104 102 98 
15. 82 94 106 114 110 108 106 100 
16. 79 96 93 89 86 82 87 83 
17. 78 97 105 104 103 102 99 96 
18. 96 115 110 108 100 96 94 93 
19. 72 98 102 99 101 98 97 94 
20. 78 97 106 105 104 105 100 97 
GROUP 'B' (LIGNOCAINE) HEART RATE (BEATS PER MINUTES) 
 
S.No. Pre induction 
1 m after 
Test drug Intubation 1 min 2 min 3 min 4 min 5 min 
1. 77 100 108 108 99 97 93 97 
2. 69 94 103 107 99 101 96 89 
3. 80 102 111 113 116 114 113 105 
4. 79 100 120 122 123 118 119 114 
5. 86 98 123 124 120 120 118 117 
6. 84 100 118 117 117 117 119 125 
7. 63 79 90 91 92 90 90 87 
8. 75 86 103 104 105 107 105 103 
9. 96 102 129 129 128 127 120 120 
10. 90 106 115 117 113 112 110 108 
11. 68 94 103 107 98 101 96 89 
12. 97 101 109 108 98 97 93 95 
13. 84 100 118 117 117 117 114 112 
14. 79 100 120 123 118 119 115 114 
15. 83 97 121 124 120 121 118 117 
16. 90 106 115 117 113 112 110 108 
17. 75 86 103 104 105 107 105 103 
18. 63 74 90 91 92 90 90 87 
19. 95 101 127 126 125 120 120 118 
20. 80 102 111 112 105 114 113 105 
 
